Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 3/2012

01-12-2012

N-TproBNP as Biomarker in Systemic Sclerosis

Authors: Tommaso Schioppo, Carolina Artusi, Teresa Ciavarella, Francesca Ingegnoli, Antonella Murgo, Silvana Zeni, Cecilia Chighizola, Pier Luigi Meroni

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2012

Login to get access

Abstract

Systemic sclerosis (SSc) is a connective tissue disorder characterized by tissue fibrosis affecting the skin and internal organs, fibroproliferative vasculopathy, and autoimmune activation. SSc still heralds a poor prognosis with significant morbidity and mortality. Early detection of organ involvement is critical as currently available treatments are most effective when started early. Many candidate biomarkers have been investigated in the past two decades. However, despite the enormous efforts, no accurate tool to predict the pattern of organ involvement and to assess disease activity has been yet identified. The N-terminal fragment of probrain natriuretic peptide (N-TproBNP) is a neurohormone released by ventricular myocytes in response to pressure overload. N-TproBNP is highly relevant for diagnosis, prognosis, and prediction of pulmonary arterial hypertension in SSc. Moreover, several studies support its potential benefit for cardiac assessment of scleroderma patients. Conversely, the role of N-TproBNP as surrogate marker of pulmonary fibrosis and skin involvement is much less clear. We provide an extensive review of the studies that have previously investigated the role of N-TproBNP as candidate biomarker in scleroderma manifestations, presenting also the findings of a recent study we conducted in a cohort of 87 SSc patients.
Literature
1.
go back to reference Geyer M, Muller-Ladner U (2011) The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 40(2):92–103PubMedCrossRef Geyer M, Muller-Ladner U (2011) The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 40(2):92–103PubMedCrossRef
2.
go back to reference Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG (2004) Natriuretic peptides, respiratory disease, and the right heart. Chest 126(4):1330–1336PubMedCrossRef Yap LB, Mukerjee D, Timms PM, Ashrafian H, Coghlan JG (2004) Natriuretic peptides, respiratory disease, and the right heart. Chest 126(4):1330–1336PubMedCrossRef
3.
go back to reference Hall C (2004) Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 6(3):257–260PubMedCrossRef Hall C (2004) Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 6(3):257–260PubMedCrossRef
4.
go back to reference Wilkins MR, Redondo J, Brown LA (1997) The natriuretic-peptide family. Lancet 349(9061):1307–1310PubMedCrossRef Wilkins MR, Redondo J, Brown LA (1997) The natriuretic-peptide family. Lancet 349(9061):1307–1310PubMedCrossRef
5.
go back to reference Helal I, Belhadj R, Mohseni A et al (2010) Clinical significance of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in hemodialysis patients. Saudi J Kidney Dis Transpl 21(2):262–268PubMed Helal I, Belhadj R, Mohseni A et al (2010) Clinical significance of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in hemodialysis patients. Saudi J Kidney Dis Transpl 21(2):262–268PubMed
6.
go back to reference Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS (2007) Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med 49(5):627–669PubMedCrossRef Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS (2007) Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med 49(5):627–669PubMedCrossRef
7.
go back to reference Carpenter CR, Keim SM, Worster A, Rosen P (2012) Brain natriuretic peptide in the evaluation of emergency department dyspnea: is there a role? J Emerg Med 42(2):197–205PubMedCrossRef Carpenter CR, Keim SM, Worster A, Rosen P (2012) Brain natriuretic peptide in the evaluation of emergency department dyspnea: is there a role? J Emerg Med 42(2):197–205PubMedCrossRef
8.
go back to reference Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347(3):161–167PubMedCrossRef Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347(3):161–167PubMedCrossRef
9.
go back to reference Harrison A, Morrison LK, Krishnaswamy P et al (2002) B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39(2):131–138PubMedCrossRef Harrison A, Morrison LK, Krishnaswamy P et al (2002) B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39(2):131–138PubMedCrossRef
10.
go back to reference Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330(7492):625PubMedCrossRef Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330(7492):625PubMedCrossRef
11.
go back to reference Hartmann F, Packer M, Coats AJ et al (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110(13):1780–1786PubMedCrossRef Hartmann F, Packer M, Coats AJ et al (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110(13):1780–1786PubMedCrossRef
12.
go back to reference Lainchbury JG, Troughton RW, Frampton CM et al (2006) NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8(5):532–538PubMedCrossRef Lainchbury JG, Troughton RW, Frampton CM et al (2006) NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8(5):532–538PubMedCrossRef
13.
go back to reference Januzzi JL Jr (2012) The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis 105(1):40–50PubMedCrossRef Januzzi JL Jr (2012) The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis 105(1):40–50PubMedCrossRef
14.
go back to reference Pimenta JM, Almeida R, Araujo JP et al (2007) Amino terminal B-type natriuretic peptide, renal function, and prognosis in acute heart failure: a hospital cohort study. J Card Fail 13(4):275–280PubMedCrossRef Pimenta JM, Almeida R, Araujo JP et al (2007) Amino terminal B-type natriuretic peptide, renal function, and prognosis in acute heart failure: a hospital cohort study. J Card Fail 13(4):275–280PubMedCrossRef
15.
go back to reference Wu AH, Omland T, Wold Knudsen C et al (2005) Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. Am J Hematol 80(3):174–180PubMedCrossRef Wu AH, Omland T, Wold Knudsen C et al (2005) Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. Am J Hematol 80(3):174–180PubMedCrossRef
16.
go back to reference Palazzuoli A, Silverberg DS, Iovine F et al (2007) Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154(4):645.e9–15CrossRef Palazzuoli A, Silverberg DS, Iovine F et al (2007) Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 154(4):645.e9–15CrossRef
17.
go back to reference Das SR, Abdullah SM, Leonard D et al (2008) Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol 102(10):1394–1398PubMedCrossRef Das SR, Abdullah SM, Leonard D et al (2008) Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol 102(10):1394–1398PubMedCrossRef
18.
go back to reference Palazzuoli A, Gallotta M, Quatrini I, Nuti R (2010) Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag 6:411–418PubMedCrossRef Palazzuoli A, Gallotta M, Quatrini I, Nuti R (2010) Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag 6:411–418PubMedCrossRef
19.
go back to reference Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25(24):2243–2278PubMedCrossRef Galie N, Torbicki A, Barst R et al (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25(24):2243–2278PubMedCrossRef
20.
go back to reference Mukerjee D, St George D, Coleiro B et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093PubMedCrossRef Mukerjee D, St George D, Coleiro B et al (2003) Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 62(11):1088–1093PubMedCrossRef
21.
go back to reference Campo A, Mathai SC, Le Pavec J et al (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182(2):252–260PubMedCrossRef Campo A, Mathai SC, Le Pavec J et al (2010) Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 182(2):252–260PubMedCrossRef
22.
go back to reference Steen V, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48(2):516–522PubMedCrossRef Steen V, Medsger TA Jr (2003) Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 48(2):516–522PubMedCrossRef
24.
go back to reference McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53(17):1573–1619PubMedCrossRef McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53(17):1573–1619PubMedCrossRef
25.
go back to reference Miyamoto S, Nagaya N, Satoh T et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 Pt 1):487–492PubMed Miyamoto S, Nagaya N, Satoh T et al (2000) Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161(2 Pt 1):487–492PubMed
26.
go back to reference Williams MH, Das C, Handler CE et al (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92(7):926–932PubMedCrossRef Williams MH, Das C, Handler CE et al (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92(7):926–932PubMedCrossRef
27.
go back to reference Mukerjee D, St George D, Knight C et al (2004) Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 43(4):461–466CrossRef Mukerjee D, St George D, Knight C et al (2004) Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 43(4):461–466CrossRef
28.
go back to reference Dimitroulas T, Giannakoulas G, Karvounis H et al (2007) Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 121(1):135–137PubMedCrossRef Dimitroulas T, Giannakoulas G, Karvounis H et al (2007) Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension. Int J Cardiol 121(1):135–137PubMedCrossRef
29.
go back to reference Choi HJ, Shin YK, Lee HJ et al (2008) The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clin Rheumatol 27(4):437–442PubMedCrossRef Choi HJ, Shin YK, Lee HJ et al (2008) The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients. Clin Rheumatol 27(4):437–442PubMedCrossRef
30.
go back to reference Ciurzynski M, Bienias P, Lichodziejewska B et al (2008) Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol 27(8):991–997PubMedCrossRef Ciurzynski M, Bienias P, Lichodziejewska B et al (2008) Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol 27(8):991–997PubMedCrossRef
31.
go back to reference Williams MH, Handler CE, Akram R et al (2006) Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27(12):1485–1494PubMedCrossRef Williams MH, Handler CE, Akram R et al (2006) Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27(12):1485–1494PubMedCrossRef
32.
go back to reference Elshamy HA, Ibrahim SE, Farouk HM, Moustafa AA, Aly IM, Osman WM (2011) N-terminal pro-brain natriuretic peptide in systemic sclerosis: new insights. Eur J Dermatol 21(5):686–690PubMed Elshamy HA, Ibrahim SE, Farouk HM, Moustafa AA, Aly IM, Osman WM (2011) N-terminal pro-brain natriuretic peptide in systemic sclerosis: new insights. Eur J Dermatol 21(5):686–690PubMed
33.
go back to reference Oravec RM, Bredemeier M, Laurino CC et al (2010) NT-proBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities. Clin Biochem 43(9):745–749PubMedCrossRef Oravec RM, Bredemeier M, Laurino CC et al (2010) NT-proBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities. Clin Biochem 43(9):745–749PubMedCrossRef
34.
go back to reference Allanore Y, Meune C (2009) N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 27(3 Suppl 54):59–63PubMed Allanore Y, Meune C (2009) N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 27(3 Suppl 54):59–63PubMed
35.
go back to reference Allanore Y, Borderie D, Avouac J et al (2008) High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58(1):284–291PubMedCrossRef Allanore Y, Borderie D, Avouac J et al (2008) High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 58(1):284–291PubMedCrossRef
36.
go back to reference Dimitroulas T, Giannakoulas G, Papadopoulou K et al (2010) Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol 29(9):957–964PubMedCrossRef Dimitroulas T, Giannakoulas G, Papadopoulou K et al (2010) Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clin Rheumatol 29(9):957–964PubMedCrossRef
37.
go back to reference Mathai SC, Bueso M, Hummers LK et al (2010) Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 35(1):95–104PubMedCrossRef Mathai SC, Bueso M, Hummers LK et al (2010) Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 35(1):95–104PubMedCrossRef
38.
go back to reference Dimitroulas T, Giannakoulas G, Karvounis H et al (2008) N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol 27(5):655–658PubMedCrossRef Dimitroulas T, Giannakoulas G, Karvounis H et al (2008) N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol 27(5):655–658PubMedCrossRef
39.
go back to reference Simeoni S, Lippi G, Puccetti A et al (2008) N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int 28(7):657–660PubMedCrossRef Simeoni S, Lippi G, Puccetti A et al (2008) N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int 28(7):657–660PubMedCrossRef
40.
go back to reference Hayakawa I, Shirasaki F, Hirano T et al (2006) Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int 26(3):270–273PubMedCrossRef Hayakawa I, Shirasaki F, Hirano T et al (2006) Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int 26(3):270–273PubMedCrossRef
41.
go back to reference Kahan A, Allanore Y (2006) Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 4):iv14–iv17CrossRef Kahan A, Allanore Y (2006) Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 4):iv14–iv17CrossRef
42.
go back to reference Perera A, Fertig N, Lucas M et al (2007) Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 56(8):2740–2746PubMedCrossRef Perera A, Fertig N, Lucas M et al (2007) Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 56(8):2740–2746PubMedCrossRef
43.
go back to reference Hanke K, Dahnrich C, Bruckner CS et al (2009) Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 11(1):R28PubMedCrossRef Hanke K, Dahnrich C, Bruckner CS et al (2009) Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 11(1):R28PubMedCrossRef
44.
go back to reference Arnett FC, Reveille JD, Goldstein R et al (1996) Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 39(7):1151–1160PubMedCrossRef Arnett FC, Reveille JD, Goldstein R et al (1996) Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 39(7):1151–1160PubMedCrossRef
45.
go back to reference Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 40(10):1157–1162CrossRef Tormey VJ, Bunn CC, Denton CP, Black CM (2001) Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology (Oxford) 40(10):1157–1162CrossRef
46.
47.
go back to reference Allanore Y, Meune C, Vonk MC et al (2010) Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 69(1):218–221PubMedCrossRef Allanore Y, Meune C, Vonk MC et al (2010) Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 69(1):218–221PubMedCrossRef
48.
go back to reference de Groote P, Gressin V, Hachulla E et al (2008) Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 67(1):31–36PubMedCrossRef de Groote P, Gressin V, Hachulla E et al (2008) Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 67(1):31–36PubMedCrossRef
49.
go back to reference Poanta L, Dadu R, Tiboc C, Rednic S, Dumitrascu D (2009) Systolic and diastolic function in patients with systemic sclerosis. Eur J Intern Med 20(4):378–382PubMedCrossRef Poanta L, Dadu R, Tiboc C, Rednic S, Dumitrascu D (2009) Systolic and diastolic function in patients with systemic sclerosis. Eur J Intern Med 20(4):378–382PubMedCrossRef
50.
go back to reference Meune C, Allanore Y, Pascal O et al (2005) Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr 6(5):351–357PubMedCrossRef Meune C, Allanore Y, Pascal O et al (2005) Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study. Eur J Echocardiogr 6(5):351–357PubMedCrossRef
51.
go back to reference Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A (2006) Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 33(12):2464–2469PubMed Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A (2006) Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 33(12):2464–2469PubMed
52.
go back to reference Czirjak L, Kumanovics G, Varju C et al (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67(1):59–63PubMedCrossRef Czirjak L, Kumanovics G, Varju C et al (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 67(1):59–63PubMedCrossRef
53.
go back to reference Meune C, Vignaux O, Kahan A, Allanore Y (2010) Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 103:46–52PubMedCrossRef Meune C, Vignaux O, Kahan A, Allanore Y (2010) Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 103:46–52PubMedCrossRef
54.
go back to reference Allanore Y, Wahbi K, Borderie D, Weber S, Kahan A, Meune C (2009) N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 68(12):1885–1889PubMedCrossRef Allanore Y, Wahbi K, Borderie D, Weber S, Kahan A, Meune C (2009) N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 68(12):1885–1889PubMedCrossRef
55.
go back to reference Montagnana M, Lippi G, Volpe A et al (2006) Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 39(9):913–917PubMedCrossRef Montagnana M, Lippi G, Volpe A et al (2006) Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 39(9):913–917PubMedCrossRef
56.
go back to reference Dimitroulas T, Giannakoulas G, Papadopoulou K et al (2010) Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 37(5):993–999PubMedCrossRef Dimitroulas T, Giannakoulas G, Papadopoulou K et al (2010) Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol 37(5):993–999PubMedCrossRef
57.
go back to reference Bussone G, Mouthon L (2011) Interstitial lung disease in systemic sclerosis. Autoimmun Rev 10(5):248–255PubMedCrossRef Bussone G, Mouthon L (2011) Interstitial lung disease in systemic sclerosis. Autoimmun Rev 10(5):248–255PubMedCrossRef
58.
go back to reference Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81(2):139–153CrossRef Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81(2):139–153CrossRef
59.
go back to reference Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66(7):940–944PubMedCrossRef Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66(7):940–944PubMedCrossRef
60.
go back to reference Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6(2):112–116PubMedCrossRef Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6(2):112–116PubMedCrossRef
61.
go back to reference Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283–1289PubMedCrossRef Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283–1289PubMedCrossRef
62.
go back to reference Tashkin DP, Elashoff R, Clements PJ et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176(10):1026–1034PubMedCrossRef Tashkin DP, Elashoff R, Clements PJ et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176(10):1026–1034PubMedCrossRef
63.
go back to reference Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970PubMedCrossRef Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970PubMedCrossRef
64.
go back to reference Takahashi H, Kuroki Y, Tanaka H et al (2000) Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 162(1):258–263PubMed Takahashi H, Kuroki Y, Tanaka H et al (2000) Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 162(1):258–263PubMed
65.
go back to reference Yanaba K, Hasegawa M, Takehara K, Sato S (2004) Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 31(6):1112–1120PubMed Yanaba K, Hasegawa M, Takehara K, Sato S (2004) Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 31(6):1112–1120PubMed
66.
go back to reference Bonella F, Volpe A, Caramaschi P et al (2011) Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 28(1):27–33PubMed Bonella F, Volpe A, Caramaschi P et al (2011) Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 28(1):27–33PubMed
67.
go back to reference (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581-590 (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23(5):581-590
68.
go back to reference Czirjak L, Foeldvari I, Muller-Ladner U (2008) Skin involvement in systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v44–v45CrossRef Czirjak L, Foeldvari I, Muller-Ladner U (2008) Skin involvement in systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v44–v45CrossRef
69.
go back to reference Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22(2):130–140PubMedCrossRef Rodnan GP, Lipinski E, Luksick J (1979) Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 22(2):130–140PubMedCrossRef
70.
go back to reference Moinzadeh P, Denton CP, Abraham D et al (2012) Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol 26(3):267–276PubMedCrossRef Moinzadeh P, Denton CP, Abraham D et al (2012) Biomarkers for skin involvement and fibrotic activity in scleroderma. J Eur Acad Dermatol Venereol 26(3):267–276PubMedCrossRef
71.
go back to reference Carlo-Stella N, Belloli L, Biondi ML, Marasini B (2009) Serum N-terminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis? Clin Rheumatol 28(2):241–242PubMedCrossRef Carlo-Stella N, Belloli L, Biondi ML, Marasini B (2009) Serum N-terminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis? Clin Rheumatol 28(2):241–242PubMedCrossRef
72.
go back to reference LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed
73.
go back to reference Vonk D, Coghlan G, Bonderman D et al (2010) The DETECT study: a two-stage, prospective, observational, cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension. Clin Exp Rheumatol 28(Supp):55 Vonk D, Coghlan G, Bonderman D et al (2010) The DETECT study: a two-stage, prospective, observational, cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension. Clin Exp Rheumatol 28(Supp):55
Metadata
Title
N-TproBNP as Biomarker in Systemic Sclerosis
Authors
Tommaso Schioppo
Carolina Artusi
Teresa Ciavarella
Francesca Ingegnoli
Antonella Murgo
Silvana Zeni
Cecilia Chighizola
Pier Luigi Meroni
Publication date
01-12-2012
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 3/2012
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-012-8312-4

Other articles of this Issue 3/2012

Clinical Reviews in Allergy & Immunology 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine